recurrent uterine sarcoma
Showing 1 - 25 of >10,000
Molecular Mechanism Study of Uterine Sarcoma
Recruiting
- Uterine Sarcoma
- Diagnostic biomarker
-
Wuhan, Hubei, ChinaYan Li
May 21, 2023
Osteogenic Sarcoma Recurrent Trial in Hackensack, Houston (Iscador*P)
Not yet recruiting
- Osteogenic Sarcoma Recurrent
-
Hackensack, New Jersey
- +1 more
Feb 3, 2023
Recurrent High Grade Uterine Cancer Trial in United States (Paclitaxel, Batiraxcept)
Not yet recruiting
- Recurrent High Grade Uterine Cancer
-
San Francisco, California
- +3 more
Apr 11, 2023
Recurrent Ovarian Cancer, Recurrent Uterine Cancer, Metastatic Cancer Trial in Toronto (RP-6306, Carboplatin, Paclitaxel)
Not yet recruiting
- Recurrent Ovarian Cancer
- +3 more
- RP-6306
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Oct 25, 2023
Uterine Cancer Trial in Philadelphia (18F-Fluoroestradiol)
Not yet recruiting
- Uterine Cancer
-
Philadelphia, PennsylvaniaAbramson Cancer Center at University of Pennsylvania
Jun 21, 2023
Retroperitoneal Sarcoma Trial in Singapore (Doxorubicin)
Recruiting
- Retroperitoneal Sarcoma
-
Singapore, SingaporeNational Cancer Centre Singapore
Jun 10, 2022
Metastatic Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma Trial in Hannover (Durvalumab and Tremelimumab,
Completed
- Metastatic Adult Soft Tissue Sarcoma
- Recurrent Adult Soft Tissue Sarcoma
- Durvalumab and Tremelimumab
- Doxorubicin
-
Hannover, GermanyMedizinische Hochschule Hannover
Jan 18, 2023
Locally Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Recurrent
Recruiting
- Locally Advanced Undifferentiated Pleomorphic Sarcoma
- +3 more
- Sintilimab
-
Houston, TexasM D Anderson Cancer Center
Jul 31, 2022
LMS - Leiomyosarcoma, Uterine Leiomyosarcoma Trial in Stanford (drug, procedure, behavioral)
Suspended
- LMS - Leiomyosarcoma
- Uterine Leiomyosarcoma
- Gemcitabine
- +5 more
-
Stanford, CaliforniaStanford University
Oct 24, 2022
Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer
Recruiting
- Endometrial Carcinoma
- +3 more
- Questionnaire Administration
-
Houston, TexasM D Anderson Cancer Center
Jun 29, 2022
Locally Advanced Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma Trial in Barcelona, Madrid, Valencia (CEB-01 membrane loaded
Recruiting
- Locally Advanced Soft Tissue Sarcoma
- Recurrent Soft Tissue Sarcoma
- CEB-01 membrane loaded with SN-38
-
Barcelona, Cataluña, Spain
- +4 more
Jul 26, 2022
Uterine Cervical Tumors, Cancer of Cervix, Cervical Cancer Trial (Cadonilimab, Nab paclitaxel)
Not yet recruiting
- Uterine Cervical Neoplasms
- +5 more
- Cadonilimab
- Nab paclitaxel
- (no location specified)
Apr 9, 2023
Cadonilimab in Recurrent or Metastatic Cervical Cancer
Not yet recruiting
- Recurrent or Metastatic Cervical Cancer
- (no location specified)
Nov 23, 2023
Uterine Microbiome in Recurrent Pregnancy Loss
Not yet recruiting
- Recurrent Pregnancy Loss, Not Pregnant
- Vaginal Microbiome
- Vaginal swab and endometrial biopsy
- (no location specified)
Aug 19, 2022
Osteosarcoma Metastatic, Ewing's Sarcoma Metastatic Trial in Miami (Chemotherapy (gemcitabine & docetaxel) plus BIO-11006)
Active, not recruiting
- Osteosarcoma Metastatic
- Ewing's Sarcoma Metastatic
- Chemotherapy (gemcitabine & docetaxel) plus BIO-11006
-
Miami, FloridaNicklaus Children's Hospital
Nov 8, 2022
Recurrent Endometrial Serous Adenocarcinoma Trial in Columbus (procedure, biological, drug)
Not yet recruiting
- Recurrent Endometrial Serous Adenocarcinoma
- Biospecimen Collection
- +4 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
May 12, 2023
AK104 Combined With I-125 Brachytherapy for Recurrent or
Not yet recruiting
- Cervical Cancer
- Iodine-125 particle brachytherapy
- AK104
- (no location specified)
Sep 25, 2023
Recurrent Pregnancy Loss Trial (isosorbide mononitrate, Placebo)
Not yet recruiting
- Recurrent Pregnancy Loss
- isosorbide mononitrate
- Placebo
- (no location specified)
Apr 18, 2022
Metastatic Ewing Sarcoma, Metastatic Osteosarcoma, Recurrent Ewing Sarcoma Trial in France (Cabozantinib S-malate, Laboratory
Active, not recruiting
- Metastatic Ewing Sarcoma
- +9 more
- Cabozantinib S-malate
- Laboratory Biomarker Analysis
-
Bordeaux, France
- +10 more
Nov 26, 2022
Cervical Cancer Recurrent Trial in Beijing (RC48 + Tislelizumab)
Recruiting
- Cervical Cancer Recurrent
- RC48 + Tislelizumab
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Sep 25, 2023